Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-?2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo.

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-?2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo.

Abstract: A mechanism is provided for invoking a multi-library application on a multiple processor system, wherein the multiple processor system comprises a Power Processing Element (PPE) and a plurality of Synergistic Processing Element (SPE). Applications including multi-libraries run in the memory of the PPE. The mechanism comprises maintaining the status of each SPE in the application running on the PPE, where there are SPE agents for capturing the instructions from the PPE in the SPEs that have been started. In response to a request for invoking a library, the PPE determines whether the number of available SPEs for invoking the library is adequate based on the current status of SPEs. If the number of available SPEs is adequate, the PPE sends a run instruction to selected SPEs. After finishing the invocation of all libraries, the PPE sends termination instructions to all started SPEs.

Abstract: A communication network includes a plurality of devices and a control unit for generating control signals to control the operation of the devices. Each device includes: a device operating circuit, a communication interface for receiving command signals for controlling operation of the devices, a control circuit coupled between the device operating circuit and the communication interface for controlling the operation of the device operating circuit part in dependency of said command signals, and a master integral to the device for receiving the control signals, for generating the command signals in response to the received control signals, and for transferring the command signals to the communication interfaces of the plurality of devices. The communication network activates one of the masters as an active master, and in case the active master fails, then it activates another master to take over as the active master.

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-?2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract: Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with a pharmaceutical carrier, excipient, or diluent. The compositions are suitable as vaccines for treating or preventing drusen and diseases associated with drusen.

Abstract: The present invention provides a method and apparatus for QR-factorizing matrix on a multiprocessor system, wherein the multiprocessor system comprises at least one core processor and a plurality of accelerators, the method comprises the steps of: iteratively factorizing each panel in the matrix until the whole matrix is factorized; wherein in each iteration, the method comprises: partitioning an unprocessed matrix part in the matrix into a plurality of blocks according to a predetermined block size; partitioning a current processed panel in the unprocessed matrix part into at least two sub panels, wherein the current processed panel is composed of a plurality of blocks; and performing QR factorization one by one on the at least two sub panels with the plurality of accelerators, and updating the data of the sub panel(s) on which no QR factorization has been performed among the at least two sub panels by using the factorization result.

Abstract: This application includes methods for detecting single nucleotide polymorphisms (SNPs) in a sample using an electronically addressable microchip having a plurality of test sites. A sample nucleic acid is electronically biased, concentrated at, and immobilized to a test site on the microchip. A mixture comprising a first labeled probe and a second labeled probe is electronically hybridized to the sample nucleic acid to form first or second hybridized complexes. The first labeled probe is perfectly complementary to the first sample nucleic acid and the second labeled probe is complementary to the sample nucleic acid and contains a nucleotide that forms a mismatch with the nucleotide at the site of the polymorphism. The first or second hybridized complexes are detected by determining a signal intensity of the label of the first or second probe.

Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, d

Abstract: A system, a controller, and a method for data storage are provided. The system includes a first storage unit, a second storage unit, and a controller. The first storage unit comprises a single-layer structure for storing data, and the second storage unit comprises a multi-layer structure for storing data. The controller is coupled to the first storage unit, the second storage unit, and a host and controls the host to set the first storage unit as a master storage device and set the second storage unit as a slave storage device. As a result, the host can recognize the first storage unit and the second storage unit as two independent storage devices for storing data. Thereby, the data storage process can be simplified.

Abstract: The present invention provides a master-slave architecture for a radio frequency RF networked lighting control system having all slave elements (ballasts) configured as backups for a network master control unit. In the system and method of the present invention a slave element can become the network master network unit without reconfiguring the network and without any human intervention. Similarly, both a master and one or more slave elements may recover from a temporary outage without necessitating reconfiguration of the network and without any human intervention.

Abstract: A method and device for integrating multiple threat security services are disclosed. The method may comprise parsing an incoming packet at a current layer and analyzing the packet with respect to multiple threat security services and so that one or more threat security services needed by the packet may be determined. According to an exemplary embodiment, the current layer may be a layer in a protocol stack constructed based on the multiple threat security services. With this method, integrated multiple threat security services may filter application data and parse network packet data via a single integrated entity, and thus the efficacy of filtering application data may be improved while computation overhead may be reduced.

Abstract: An exemplary refractive-index sensor includes a photonic crystal microcavity structure, a light source, and a detector. The photonic crystal microcavity structure includes a photonic crystal layer having first holes and a second hole defined therein. The first holes are arranged in a regular pattern of staggered parallel rows. The second hole is at an approximate center of the regular pattern, instead of a first hole. A diameter of the second hole is different from that of the first holes. The first holes at each of opposite ends of the row having the second hole are omitted, thereby defining an input waveguide and an output waveguide. The light source is adjacent to the input waveguide. The detector is adjacent to the output waveguide.

Abstract: A network (20) employs a wireless network topology (30), a wireless network manager (40). Network (20) further employs a wireless device (70) and wireless device manager (80) pairing and/or a wireless system (90) and a wireless system manager (100) pairing. Managers (40, 80) cooperatively control an operating profile and monitor an operational status of the device (70). Managers (40, 100) cooperatively control an operating profile and monitor an operational status of system (90). Manager (40) can be installed on a computer (150, 170) and wirelessly communicate within network (20) via a wireless control device (160, 180) employing a port connector (161, 181) that can be plugged into a port (151, 171) of the computer (150, 170). Device (70) or system (90) can implement a digital ballast (120) that determines an average power consumption of the digital ballast (120) drawn by a power interface (121) of digital ballast (120).

Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, d

Abstract: An exemplary refractive-index sensor includes a photonic crystal microcavity structure, a light source, and a detector. The photonic crystal microcavity structure includes a photonic crystal layer having first holes and a second hole. The first holes are arranged in a pattern of staggered parallel rows. The second hole is located at an approximate center point of the middle row of the pattern rather than a first hole. A diameter of the second hole is less than that of each of the first holes. Some of the first holes disposed at each of opposite ends of a diagonal row having the second hole are omitted to define an input waveguide and an output waveguide. The light source is adjacent to the input waveguide. The detector is adjacent to the output waveguide.

Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, d

Abstract: Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea,